Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lacoste

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidineM J Millan, F Lejeune, A Gobert, et al.
The American Journal of Pathology|February 10, 2000
Twin-to-twin transfusion syndrome. Role of the fetal renin-angiotensin systemD Mahieu-Caputo, M Dommergues, A L Delezoide, et al.
Journal of Medicinal Chemistry|August 29, 1997
(S)-spiro[(1,3-diazacyclopent-1-ene)-5,2'-(7'-methyl-1',2',3',4'- tetrahydronaphthalene)]: resolution, stereospecific synthesis, and preliminary pharmacological characterization as a partial alpha-adrenergic agonistA A Cordi, J M Lacoste, F Le Borgne, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidineM J Millan, A Dekeyne, A Newman-Tancredi, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidineM J Millan, F Lejeune, A Gobert, et al.
The American Journal of Pathology|February 10, 2000
Twin-to-twin transfusion syndrome. Role of the fetal renin-angiotensin systemD Mahieu-Caputo, M Dommergues, A L Delezoide, et al.
Journal of Medicinal Chemistry|August 29, 1997
(S)-spiro[(1,3-diazacyclopent-1-ene)-5,2'-(7'-methyl-1',2',3',4'- tetrahydronaphthalene)]: resolution, stereospecific synthesis, and preliminary pharmacological characterization as a partial alpha-adrenergic agonistA A Cordi, J M Lacoste, F Le Borgne, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidineM J Millan, A Dekeyne, A Newman-Tancredi, et al.
Pageof 7